BioSpace News Archive

Realm Therapeutics plc (AIM: RLM) (the Company or Realm), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces it publicly filed a registration statement with the United States Securities and Exchange Commission (the U.S. SEC) in connection with a proposed listing of American Depositary Shares (ADSs) representing the Company’s ordinary shares on the Nasdaq Global Market (Nasdaq)

Clinigen Group plc has partnered with Mitsubishi Tanabe Pharma Corporation (‘MTPC’), to initiate a Managed Access Program (also known as an Early Access Program) in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (‘ALS’).

Drug developer Berlin Cures today announced the formation of a Scientific Advisory Board (SAB) and the appointment of its first two members, Prof. Beda M. Stadler and Prof. Wilhelm Vetter.

Centogene, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced a clinical development collaboration with Orphazyme A/S.

Robocath announces during the EuroPCR congress that its first robotic solution, R-OneTM, met all its primary efficacy and safety endpoints in the first pre-clinical study.

ReCor Medical announced today that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients.

--Biologics Expert Paul Parren Joins as Head of R&D--

Genome editing company adds drug development expert in pursuit of breakthrough medicines for pediatric patients

The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment.

Published studies show insufficient bowel prep can occur in over 55% of inpatient cases and lead to average of 2 day hospital stay extension and as much as $8,000 in additional costs